Attenuating effect of Fufang Xueshuantong Capsule on kidney function in diabetic nephropathy model

Journal of Natural Medicines

Volumn 67, Issue 1, 2013, Pages 86-97

  Zhang, Qian ^a   Xiao, Xinhua ^a   Li, Ming ^a   Li, Wenhui ^a   Yu, Miao ^a   Zhang, Huabing ^a   Sun, Xiaofang ^a   Mao, Lili ^a   Xiang, Hongding ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

Diabetic nephropathy; Fufang Xueshuantong Capsule; Gene array; Podocyte

Indexed keywords

ALBUMIN; CHINESE DRUG; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; COLLAGEN TYPE 1 ALPHA 2; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; CYTOCHROME P450; CYTOCHROME P450 FAMILY 2 SUBFAMILY C POLYPEPTIDE 23; FUFANG XUESHUANTONG; NEPHRIN; NITROGEN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIET RESTRICTION; DRUG CAPSULE; DRUG EFFECT; DRUG MEGADOSE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; LOW DRUG DOSE; MALE; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; NONHUMAN; NUTRIENT; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUGS, CHINESE HERBAL; MALE; RATS; RATS, WISTAR;

EID: 84871330414     PISSN: 13403443     EISSN: 18610293     Source Type: Journal    
DOI: 10.1007/s11418-012-0654-y     Document Type: Article

References (37)

1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053 (Pubitemid 38579764)
2. Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, Yoo SJ, Rouillon A, Weir MR (2005) An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 48:17-26 (Pubitemid 40174652)
3. Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P (2000) Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 26:8-14 (Pubitemid 30618351)
4. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (2010) US renal data systems: USRDS 2010 annual data report: Atlas of end stage renal disease in the United States. http://www.usrds.org/2010/view/default.asp
5. Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127-1133 (Pubitemid 29466226)
6. White KE, Marshall SM, Bilous RW (2008) Prevalence of atubular glomeruli in type 2 diabetic patients with nephropathy. Nephrol Dial Transpl 23:3539-3545
7. Xing YW, Tang WJ, Zou JJ, Shi YQ (2010) Protective effect of compound Xueshuantong Capsule against damage of diabetic nephropathy in rat diabetic model. Acad J Second Mil Med Univ 30:1091-1094 (Chinese)
8. Lang J, Cao H, Wei A (1998) Comparative study on effect of Panax Notoginseng and Ticlid in treating early nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi 18:727-729 (Chinese)
9. Sugano M, Yamato H, Hayashi T, Ochiai H, Kakuchi J, Goto S, Nishijima F, Lino N, Kazama JJ, Takeuchi T, Mokuda O, Ishikawa T, Okazaki R (2006) High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: A new rat model of diabetic nephropathy. Nutr Metab Cardiovasc Dis 16:447-484 (Pubitemid 44466387)
10. Huang JH, Huang XH, Chen ZY, Zheng QS, Sun RY (2004) Dose conversion among different animals and healthy volunteers in pharmacological study. Chin J Clin Pharmacol Ther 9:1069-1072
11. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E (1990) Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 346:371-374 (Pubitemid 20226042)
12. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863-14868 (Pubitemid 29003722)
13. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4:P3
14. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA (2003) Identifying biological themes within lists of genes with EASE. Genome Biol 4:R70
15. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods 25:402-408 (Pubitemid 34164012)
16. Gross ML, EI-Shakmak A, Szabo A, Koch A, Kuhlmann A, Munter K, Ritz E, Amann K (2003) ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 46:856-868 (Pubitemid 36831416)
17. Xuejiang W, Ichikawa H, Konishi T (2001) Antioxidant potential of qizhu tang, a Chinese herbal medicine, and the effect on cerebral oxidative damage after ischemia reperfusion in rats. Biol Pharm Bull 24:558-563 (Pubitemid 32499486)
18. Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, Xu F, Wang BS, Mao JH, Shen ZX, Chen SJ, Chen Z (2008) Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 105:4826-4831 (Pubitemid 351753831)
19. Yang CY, Xie ZG, Cheng WB, Jiang X, Chen ZH (2009) Effects of Panax notogenseng saponins on anti-hyperglycemic, anti-obese and prevention from kidney pathological changes in KK-Ay mice. Zhong Yao Cai 32:1571-1576 (Chinese)
20. Chen ZH, Li J, Liu J, Zhao Y, Zhang P, Zhang MX, Zhang L (2008) Saponins isolated from the root of Panax notoginseng showed significant anti-diabetic effects in KK-Ay mice. Am J Chin Med 36:939-951
21. Sang Z, Zhou L, Fan X, McCrimmon RJ (2010) Radix astragali (huangqi) as a treatment for defective hypoglycemia counterregulation in diabetes. Am J Chin Med 38:1027-1038
22. Luo P, Tan Z, Zhang Z, Li H, Mo Z (2008) Inhibitory effects of salvianolic acid B on the high glucose-induced mesangial proliferation via NF-kappaB-dependent pathway. Bio Pharm Bull 31:1381-1386 (Pubitemid 351930651)
23. Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P (2003) Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 52:1031-1035 (Pubitemid 36384274)
24. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, Camussi G (2003) Nephrin expression is reduced in human diabetic nephropathy, evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52:1023-1030 (Pubitemid 36384273)
25. Vleming LJ, Baelde JJ, Westendorp RW, Daha MR, van Es LA, Bruijn JA (1997) The glomerular deposition of PAS positive material correlates with renal function in human kidney diseases. Clin Nephrol 47:158-167 (Pubitemid 27119708)
26. Sharma K, Jin Y, Guo J, Ziyadeh FN (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530
27. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685-700 (Pubitemid 36724933)
28. Nett PC, Ortmann J, Celeiro J, Haas E, Hofmann-Lehmann R, Tornillo L, Terraciano LM, Barton M (2006) Transcriptional regulation of vascular bone morphogenetic protein by endothelin receptors in early autoimmune diabetes mellitus. Life Sci 78:2213-2218
29. Stelnicki EJ, LongakerMT HolmesD, Vanderwall K, Largman C, Harrison MR, Hoffman WY (1998) Bone morphogenetic protein-2 induces scar formation and skin maturation in the second trimester fetus. Plast Reconstr Surg 101:12-19 (Pubitemid 28022915)
30. Faler BJ, Macsata RA, Plummer D, Mishra L, Sidawy AN (2006) Transforming growth factor-beta and wound healing. Perspect Vasc Surg Endovasc Ther 18:55-62
31. Hocevar BA, Howe PH (2000) Analysis of TGF-beta-mediated synthesis of extracellular matrix components. Methods Mol Biol 142:55-65
32. Sharma K, Ziyadeh FN (1995) Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-b as a key mediator. Diabetes 44:1139-1146
33. Ziyadeh FN, Hoffman BB, Han DC, Iqlesias-De La Crus MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020 (Pubitemid 30460765)
34. Ito Y, Goldschmeding YR, Bende RJ, Claessen N, Chand M, Kleii L, Rabelink T, Weening J, Aten J (2001) Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J Am Soc Nephrol 12:472-484 (Pubitemid 32180016)
35. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275:40504-40510 (Pubitemid 32064687)
36. Wang MH (2006) Renal cytochrome P450-derived eicosanoids and hypertension. Curr Hyperten Rev 2:227-236 (Pubitemid 44304632)
37. Natarajan R, Reddy MA (2003) HETEs/EETs in renal glomerular and epithelial cell functions. Curr Opin Pharmacol 3:198-203 (Pubitemid 36416559)